10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

KLDC2 Antibody (C-term) Blocking Peptide

Synthetic peptide
Catalog # BP4819b

Specification

KLDC2 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession Q9Y2U9

KLDC2 Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 23588

Other Names
Kelch domain-containing protein 2, Hepatocellular carcinoma-associated antigen 33, Host cell factor homolog LCP, Host cell factor-like protein 1, HCLP-1, KLHDC2, HCA33

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

KLDC2 Antibody (C-term) Blocking Peptide - Protein Information

Name KLHDC2 {ECO:0000303|PubMed:16964437, ECO:0000312|HGNC:HGNC:20231}

Function
Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex of the DesCEND (destruction via C-end degrons) pathway, which recognizes a C-degron located at the extreme C terminus of target proteins, leading to their ubiquitination and degradation (PubMed:29779948, PubMed:29775578, PubMed:30526872). The C-degron recognized by the DesCEND pathway is usually a motif of less than ten residues and can be present in full-length proteins, truncated proteins or proteolytically cleaved forms (PubMed:29779948, PubMed:29775578, PubMed:30526872). The CRL2(KLHDC2) complex specifically recognizes proteins with a diglycine (Gly-Gly) at the C-terminus, leading to their ubiquitination and degradation (PubMed:29779948, PubMed:29775578, PubMed:30526872). The CRL2(KLHDC2) complex mediates ubiquitination and degradation of truncated SELENOK and

SELENOS selenoproteins produced by failed UGA/Sec decoding, which end with a diglycine (PubMed:26138980, PubMed:30526872). The CRL2(KLHDC2) complex also recognizes proteolytically cleaved proteins ending with Gly-Gly, such as the N-terminal fragment of USP1, leading to their degradation (PubMed:29775578, PubMed:30526872). May also act as an indirect repressor of CREB3-mediated transcription by interfering with CREB3-DNA-binding (PubMed:11384994).

Cellular Location
Nucleus

Tissue Location
Widely expressed, with high levels in skeletal muscle, heart, pancreas and liver (PubMed:11384994, PubMed:16964437) Undetectable in peripheral blood leukocytes (PubMed:16964437)

KLDC2 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

KLDC2 Antibody (C-term) Blocking Peptide - Images

KLDC2 Antibody (C-term) Blocking Peptide - Background

KLDC2 represses CREB3-mediated transcription by interfering with CREB3-DNA binding.

KLDC2 Antibody (C-term) Blocking Peptide - References

Chin, K.T., et al. Mol. Cell. Biochem. 296 (1-2), 109-119 (2007) Ewing, R.M., et al. Mol. Syst. Biol. 3, 89 (2007)Wang, Y., et al. J. Immunol. 169(2):1102-1109(2002)